A Phase 2 interventional study of Fluticasone furoate and Matching placebo in Asthma, sponsored by GlaxoSmithKline. Completed at 5 sites in United States. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-03-23.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.
Among the 40 studies testing fluticasone furoate in Asthma, this one is the 31st largest by enrollment, is one of 7 that started in 2010, is one of 12 in phase 2, and was the 17th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 5 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 102 across the 40 interventional studies. Of the 35 that completed or were terminated, 22 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 40 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 185th largest by enrollment of the 238 interventional ones that give a count, is one of 34 that started in 2010, is one of 59 in phase 2, and was the 109th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing fluticasone furoate in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing fluticasone furoate in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will investigate the effect of dosing with flutucasone furoate in asthmatic subjects aged 5-11 years of age. A randomized, two-way crossover, with placebo control, over a 14 day treatment period, it will investigate safety, tolerability, pharmacokinetics and serum cortisol levels.
This study will investigate the effect of dosing with fluticasone furoate 100 μg (micrograms) in asthmatic subjects aged 5-11 years of age. Fluticasone furoate is currently under development as the inhaled corticosteroid component of a combination product containing an inhaled corticosteroid and a long-acting beta-agonist.
The study will be a randomized two-way crossover, with a placebo control. During each treatment period subjects will receive a daily dose via a novel dry powder inhaler for 14 days. Approximately 26 subjects will be recruited to this study, with the aim that 20 will complete the study. Safety, tolerability, pharmacokinetics and serum cortisol levels will be investigated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(8-11 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Day 2-13 = home dosing
Drug: Fluticasone furoate
(8-11 years old) Repeat dose session: matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
Drug: Matching placebo
(5-7 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
Drug: Fluticasone furoate
(5-7 years old) Repeat dose session: Matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
Drug: Matching placebo
Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.
Time frame: From the start of study medication until Week 11 (Visit 6)/Early Withdrawal
Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelets, and white blood cell (WBC) count at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 44)
Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of hemoglobin and MCHC at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 44)
Reticulocyte and Red Blood Cell (RBC) Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of reticulocyte and RBCs at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 44)
Hematocrit Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of hematocrit at Day 14 of the respective treatment period. Hematocrit is a measure of the percentage of the volume of the whole blood that is composed of red blood cells, as determined by separation of red blood cells from the plasma (usually by centrifugation).
Time frame: Day 14 of the respective treatment period (up to Study Day 44)
Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of MCV at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 44)
Mean Corpuscle Hemoglobin (MCH) Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of MCH at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 44)
Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 44)
Albumin and Total Protein Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of albumin and total protein at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 44)
Calcium, Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of calcium, chloride, carbon dioxide content/bicarbonate (CO2/BI), glucose, potassium, sodium, and urea/BUN at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 44)
Total Bilirubin, Creatinine, and Uric Acid Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of total bilirubin, creatinine, and uric acid at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 44)
Peak Expiratory Flow on Day 1 and Day 14 of the Respective Treatment Period
Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF is calculated as the maximum of three readings taken at each timepoint for each participant. Baseline is defined as the maximum pre-dose measurement at Day 1 for each period.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 44)
Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Baseline and Day 14 of the Respective Treatment Period
SBP and DBP were measured at Baseline and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1 for each period.
Time frame: Baseline and Day 14 of the respective treatment period (up to Study Day 44)
Heart Rate at Baseline and Day 14 of the Respective Treatment Period
Heart rate (HR) was measured at Baseline and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1 for each period.
Time frame: Baseline and Day 14 of the respective treatment period (up to Study Day 44)
Change From Baseline in the Indicated Electrocardiographic (ECG) Parameters at the Indicated Time Points on Day 14 of the Respective Treatment Period
PR, QRS, QT, QTcB, QTcF, and RR were measured at Baseline and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1 for each period. Change from Baseline was calculated as the value at Day 14 minus the Baseline value. QTcB is the QT duration corrected for heart rate by Bazett's formula. QTcF is the QT duration corrected for heart rate by Fridericia's formula.
Time frame: Baseline and Day 14 of the respective treatment period (up to Study Day 44)
AUC(0-t) on Day 14 of the Respective Treatment Period
Area under the concentration-time (AUC(0-t)) curve from time zero (pre-dose) to the last time of quantifiable concentration of FF on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period. Due to non-quantifiable values, it was not possible to derive AUC(0-12).
Time frame: Day 14 of the respective treatment period
Cmax on Day 14 of the Respective Treatment Period
Cmax is defined as the maximum observed concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period
Tmax and t at Day 14 of the Respective Treatment Period
tmax is defined as the time to reach the observed maximum concentration, and t is defined as the time of the last observed quantifiable concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period
Serum Cortisol Weighted Mean (0-12 Hours) on Day 14 of the Respective Treatment Period
Serum cortisol weighted mean was determined for each participant over the time period 0-12 hours on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period
Average Oropharyngeal Cross-sectional Area on Days 1 and 14 of the Respective Treatment Period
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
Time frame: Days 1 and 14 of the respective treatment period
Distance of Assessment on Days 1 and 14 of the Respective Treatment Period
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Distance of assessment is defined as the distance (length measured in centimeters \[cm\]) estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of each treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
Time frame: Days 1 and 14 of the respective treatment period
Oropharyngeal Volume on Days 1 and 14 of the Respective Treatment Period
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Oropharyngeal volume is defined as the volume (cm\^3) of the mouth and throat estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
Time frame: Days 1 and 14 of the respective treatment period
Average Flow Rate and Peak Inspiratory Flow Rate (PIFR) on Days 1 and 14 of the Respective Treatment Period
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Average flow rate is defined as the average inspiratory flow rate (Liters \[L\]/min) across the inhalation profile when inhaling across the resistance of the inhaler. PIFR is defined as the Peak Inspiratory Flow Rate (L/min) of the inhalation profile when inhaling across the resistance of the inhaler.The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the average flow rate and PIFR were determined.
Time frame: Day 1 and Day 14 of the respective treatment period
Inhalation Time on Days 1 and 14 of the Respective Treatment Period
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhalation time is defined as the duration of the inhalation(s) when inhaling across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalation time was determined.
Time frame: Day 1 and Day 14 of the respective treatment period
Inhaled Volume on Days 1 and 14 of the Respective Treatment Period
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhaled volume is defined as the volume of air (Liters) inhaled during the inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalaled volume was determined.
Time frame: Day 1 and Day 14 of the respective treatment period
Peak Pressure Drop on Days 1 and 14 of the Respective Treatment Period
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Peak pressure drop is defined as the maximum pressure drop (kilopascal \[kPa\]) achieved during inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was calculated for each day (Days 1 and 14 of the respective treatment period), and used for subsequent modeling and prediction of dose emission attributes.
Time frame: Day 1 and Day 14 of the respective treatment period
Total Emitted Dose (TED) on Days 1 and 14 of the Respective Treatment Period
The total emitted dose (TED) is defined as the mass (micrograms) of the nominal dose that passes beyond the throat. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted total emitted dose.
Time frame: Day 1 and Day 14 of the respective treatment period
Ex-throat Dose (ETD) and ETD <2 Microns on Days 1 and 14 of the Respective Treatment Period
The ex-throat dose (ETD) and the "nominal ETD" is the mass (micrograms) of active investigational material that passes beyond the throat, nominal being the mean.The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted ETD and ETD \<2 microns.
Time frame: Day 1 and Day 14 of the respective treatment period
Participants were enrolled into one of two cohorts based upon age; the younger cohort was enrolled after a review of the safety/pharmacokinetic data of at least six participants from the older cohort. Each participant was assigned to treatment randomly; assignment was not to be influenced by whether participants were in Cohort 1 or Cohort 2.
| Milestone | Sequence 1: FF 100 µg Followed by Placebo | Sequence 2: Placebo Followed by FF 100 µg |
|---|---|---|
| Started | 14 | 13 |
| Completed | 12 | 12 |
| Not completed | 2 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Milestone | Sequence 1: FF 100 µg Followed by Placebo | Sequence 2: Placebo Followed by FF 100 µg |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
| Milestone | Sequence 1: FF 100 µg Followed by Placebo | Sequence 2: Placebo Followed by FF 100 µg |
|---|---|---|
| Started | 12 | 12 |
| Completed | 11 | 11 |
| Not completed | 1 | 1 |
| Withdrew: Physician decision | 1 | 1 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.
| participants | Placebo | FF 100 µg |
|---|---|---|
| Any AE | 4 | 8 |
| Any SAE | 0 | 0 |
Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelets, and white blood cell (WBC) count at Day 14 of the respective treatment period.
| 10^9 cells per liter (GI/L) | Placebo | FF 100 µg |
|---|---|---|
| Basophils, n=23, 21 | 0.022 ± 0.0153 | 0.022 ± 0.0154 |
| Eosinophils, n=23, 21 | 0.308 ± 0.2204 | 0.252 ± 0.2182 |
| Lymphocytes, n=23, 21 | 2.595 ± 0.7834 | 2.430 ± 0.6563 |
| Monocytes, n=23, 21 | 0.280 ± 0.1669 | 0.270 ± 0.1204 |
| Total neutrophils, n=23, 21 | 2.740 ± 1.2091 | 3.209 ± 1.3103 |
| Platelets, n=23, 20 | 266.4 ± 48.59 | 263.3 ± 55.90 |
| WBCs, n=23, 21 | 5.94 ± 1.696 | 6.18 ± 1.513 |
Blood samples were collected for the measurement of hemoglobin and MCHC at Day 14 of the respective treatment period.
| Grams per liter (g/L) | Placebo | FF 100 µg |
|---|---|---|
| Hemoglobin, n=23, 21 | 129.1 ± 7.15 | 129.6 ± 6.50 |
| MCHC, n=23, 21 | 336.4 ± 7.66 | 336.6 ± 7.80 |
Blood samples were collected for the measurement of reticulocyte and RBCs at Day 14 of the respective treatment period.
| 10^12 cells per liter (TI/L) | Placebo | FF 100 µg |
|---|---|---|
| Reticulocytes, n=23, 21 | 0.04952 ± 0.024497 | 0.04499 ± 0.021309 |
| RBCs, n=23, 21 | 4.43 ± 0.277 | 4.46 ± 0.296 |
Blood samples were collected for the measurement of hematocrit at Day 14 of the respective treatment period. Hematocrit is a measure of the percentage of the volume of the whole blood that is composed of red blood cells, as determined by separation of red blood cells from the plasma (usually by centrifugation).
| percentage of red blood cells in blood | Placebo | FF 100 µg |
|---|---|---|
| Hematocrit Values at Day 14 of the Respective Treatment Period | 0.3840 ± 0.02621 | 0.3854 ± 0.02296 |
Blood samples were collected for the measurement of MCV at Day 14 of the respective treatment period.
| 10^15 femtoliters (fL) per cell | Placebo | FF 100 µg |
|---|---|---|
| Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period | 86.8 ± 4.05 | 86.9 ± 4.40 |
Blood samples were collected for the measurement of MCH at Day 14 of the respective treatment period.
| 10^12 picograms (pg) per cell | Placebo | FF 100 µg |
|---|---|---|
| Mean Corpuscle Hemoglobin (MCH) Values at Day 14 of the Respective Treatment Period | 29.18 ± 1.279 | 29.24 ± 1.458 |
Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Day 14 of the respective treatment period.
| International units per liter (IU/L) | Placebo | FF 100 µg |
|---|---|---|
| ALT, n=22, 20 | 12.2 ± 3.06 | 13.0 ± 6.04 |
| ALP, n=22, 20 | 257.8 ± 59.24 | 260.7 ± 64.15 |
| AST, n=22, 19 | 26.8 ± 4.39 | 26.1 ± 4.53 |
| GGT, n=22, 20 | 14.3 ± 3.58 | 15.4 ± 4.50 |
Blood samples were collected for the measurement of albumin and total protein at Day 14 of the respective treatment period.
| Grams per liter | Placebo | FF 100 µg |
|---|---|---|
| Albumin, n=22, 20 | 43.0 ± 2.26 | 42.9 ± 1.83 |
| Total protein, n=22, 20 | 67.8 ± 2.98 | 67.8 ± 2.57 |
Blood samples were collected for the measurement of calcium, chloride, carbon dioxide content/bicarbonate (CO2/BI), glucose, potassium, sodium, and urea/BUN at Day 14 of the respective treatment period.
| Millimoles per liter (mmol/L) | Placebo | FF 100 µg |
|---|---|---|
| Calcium, n=20, 19 | 2.371 ± 0.0791 | 2.366 ± 0.0626 |
| Chloride, n=22, 20 | 105.2 ± 1.93 | 104.7 ± 1.72 |
| CO2 content/bicarbonate, n=20, 19 | 17.4 ± 2.04 | 17.8 ± 1.86 |
| Glucose, n=22, 20 | 5.13 ± 0.614 | 4.86 ± 0.319 |
| Potassium, n=20, 19 | 4.24 ± 0.2564 | 4.24 ± 0.289 |
| Sodium, n=22, 20 | 138.3 ± 1.55 | 137.4 ± 1.54 |
| Urea/BUN, n=22, 20 | 4.66 ± 0.993 | 4.83 ± 1.331 |
Blood samples were collected for the measurement of total bilirubin, creatinine, and uric acid at Day 14 of the respective treatment period.
| Micromoles per liter (µmol/L) | Placebo | FF 100 µg |
|---|---|---|
| Total bilirubin, n= 22, 20 | 5.9 ± 2.27 | 5.6 ± 1.23 |
| Creatinine, n= 22, 20 | 39.89 ± 7.775 | 40.62 ± 8.421 |
| Uric acid, n= 22, 20 | 237.7 ± 65.46 | 234.5 ± 70.97 |
Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF is calculated as the maximum of three readings taken at each timepoint for each participant. Baseline is defined as the maximum pre-dose measurement at Day 1 for each period.
| liters/minute | Placebo | FF 100 µg |
|---|---|---|
| Day 1, Baseline, n=25, 25 | 242.3 ± 77.68 | 238.4 ± 64.98 |
| Day 1, 15 minutes post-dose, n=25, 25 | 242.1 ± 78.98 | 238.2 ± 58.97 |
| Day 1, 30 minutes post-dose, n=25, 25 | 249.2 ± 78.07 | 246.0 ± 62.65 |
| Day 1, 1 hour post-dose, n=25, 25 | 247.7 ± 72.54 | 247.0 ± 64.75 |
| Day 1, 2 hours post-dose, n=25, 25 | 252.3 ± 89.08 | 252.6 ± 61.77 |
| Day 14, Pre-dose, n=24, 23 | 242.0 ± 73.60 | 240.6 ± 83.88 |
| Day 14, 30 minutes post-dose, n=23, 23 | 246.1 ± 81.17 | 238.8 ± 88.78 |
| Day 14, 1 hours post-dose, n=23, 23 | 247.0 ± 77.95 | 237.6 ± 78.66 |
| Day 14, 2 hours post-dose, n=23, 23 | 249.5 ± 74.09 | 242.3 ± 72.02 |
| Day 14, 4 hours post-dose, n=23, 23 | 250.6 ± 82.43 | 246.2 ± 70.43 |
| Day 14, 7 hours post-dose, n=23, 23 | 246.3 ± 79.07 | 232.1 ± 59.82 |
| Day 14, 12 hours post-dose, n=23, 23 | 241.9 ± 75.80 | 245.6 ± 76.68 |
SBP and DBP were measured at Baseline and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1 for each period.
| Millimeters of mercury (mmHg) | Placebo | FF 100 µg |
|---|---|---|
| Day 1 SBP, Predose, n=25, 26 | 103.1 ± 9.29 | 102.9 ± 9.68 |
| Day 1 SBP, 30 minutes, n=25, 26 | 101.2 ± 8.57 | 103.8 ± 10.44 |
| Day 1 SBP, 1 hour, n=25, 26 | 102.7 ± 11.11 | 105.2 ± 11.19 |
| Day 1 SBP, 2 hours, n=25, 26 | 102.9 ± 9.98 | 103.9 ± 9.04 |
| Day 14 SBP, Predose, n=24, 23 | 101.8 ± 8.04 | 102.1 ± 9.92 |
| Day 14 SBP, 1 hour, n=23, 23 | 102.6 ± 9.14 | 103.1 ± 8.04 |
| Day 14 SBP, 4 hours, n=23, 23 | 102.0 ± 9.07 | 102.7 ± 9.43 |
| Day 14 SBP, 7 hours, n=23, 23 | 103.4 ± 9.34 | 103.9 ± 9.88 |
| Day 14 SBP, 12 hours, n=23, 23 | 103.2 ± 7.42 | 106.3 ± 10.61 |
| Day 1 DBP, Predose, n=25, 26 | 62.0 ± 9.71 | 61.7 ± 7.66 |
| Day 1 DBP, 30 minutes, n=25, 26 | 63.0 ± 9.09 | 62.6 ± 6.39 |
| Day 1 DBP, 1 hour, n=25, 26 | 61.4 ± 8.69 | 62.3 ± 8.73 |
| Day 1 DBP, 2 hours, n=25, 26 | 63.0 ± 8.34 | 61.2 ± 8.39 |
| Day 14 DBP, Predose, n=24, 23 | 61.3 ± 6.91 | 61.4 ± 6.81 |
| Day 14 DBP, 1 hour, n=23, 23 | 63.9 ± 10.14 | 62.7 ± 6.88 |
| Day 14 DBP, 4 hours, n=23, 23 | 60.4 ± 8.81 | 60.5 ± 6.73 |
| Day 14 DBP, 7 hours, n=23, 23 | 61.8 ± 9.27 | 62.3 ± 8.23 |
| Day 14 DBP, 12 hours, n=23, 23 | 62.0 ± 8.10 | 63.9 ± 8.68 |
Heart rate (HR) was measured at Baseline and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1 for each period.
| Beats per minute | Placebo | FF 100 µg |
|---|---|---|
| Day 1, Baseline, n=25, 26 | 78.7 ± 13.18 | 75.9 ± 11.48 |
| Day 1, 30 minutes, n=25, 26 | 78.5 ± 13.99 | 75.5 ± 10.90 |
| Day 1, 1 hour, n=25, 26 | 78.6 ± 12.62 | 77.6 ± 11.49 |
| Day 1, 2 hours, n=25, 26 | 80.6 ± 13.30 | 79.6 ± 11.78 |
| Day 14, Predose, n=24, 23 | 76.8 ± 13.52 | 74.5 ± 10.60 |
| Day 14, 1 hour, n=23, 23 | 80.3 ± 14.76 | 76.2 ± 8.60 |
| Day 14, 4 hours, n=23, 23 | 78.2 ± 10.46 | 77.7 ± 9.77 |
| Day 14, 7 hours, n=23, 23 | 83.1 ± 14.65 | 81.2 ± 12.13 |
| Day 14, 12 hours, n=23, 23 | 83.6 ± 11.70 | 81.1 ± 10.71 |
Area under the concentration-time (AUC(0-t)) curve from time zero (pre-dose) to the last time of quantifiable concentration of FF on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period. Due to non-quantifiable values, it was not possible to derive AUC(0-12).
| picograms*hour per milliliter (pg*hr/mL) | Placebo | FF 100 µg |
|---|---|---|
| AUC(0-t) on Day 14 of the Respective Treatment Period | — | 91.29 (63.24 to 131.78) |
Cmax is defined as the maximum observed concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period.
| picograms per milliliter (pg/mL) | Placebo | FF 100 µg |
|---|---|---|
| Cmax on Day 14 of the Respective Treatment Period | — | 24.68 (20.24 to 30.10) |
tmax is defined as the time to reach the observed maximum concentration, and t is defined as the time of the last observed quantifiable concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period.
| hours | Placebo | FF 100 µg |
|---|---|---|
| tmax | — | 0.863 ± 0.7926 |
| t | — | 6.953 ± 4.0875 |
Serum cortisol weighted mean was determined for each participant over the time period 0-12 hours on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period.
| nanomoles per Liter | Placebo | FF 100 µg |
|---|---|---|
| Serum Cortisol Weighted Mean (0-12 Hours) on Day 14 of the Respective Treatment Period | 178.76 (157.43 to 202.97) | 150.41 (132.91 to 170.22) |
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
| centimeters squared (cm^2) | Placebo | FF 100 µg |
|---|---|---|
| Day 1, n=14, 18 | 4.06 ± 1.875 | 4.24 ± 1.677 |
| Day 14, n= 12, 12 | 5.49 ± 1.586 | 4.58 ± 1.497 |
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Distance of assessment is defined as the distance (length measured in centimeters \[cm\]) estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of each treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
| centimeters (cm) | Placebo | FF 100 µg |
|---|---|---|
| Day 1, n=14, 18 | 18.63 ± 1.736 | 18.69 ± 1.432 |
| Day 14, n= 12, 12 | 19.37 ± 1.823 | 18.61 ± 1.942 |
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Oropharyngeal volume is defined as the volume (cm\^3) of the mouth and throat estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
| cubic centimeters (cm^3) | Placebo | FF 100 µg |
|---|---|---|
| Day 1, n=14, 18 | 74.19 ± 32.402 | 78.86 ± 31.092 |
| Day 14, n= 12, 12 | 106.31 ± 33.188 | 86.22 ± 34.363 |
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Average flow rate is defined as the average inspiratory flow rate (Liters \[L\]/min) across the inhalation profile when inhaling across the resistance of the inhaler. PIFR is defined as the Peak Inspiratory Flow Rate (L/min) of the inhalation profile when inhaling across the resistance of the inhaler.The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the average flow rate and PIFR were determined.
| Liters per minute (L/min) | Placebo | FF 100 µg |
|---|---|---|
| Day 1 Average flow rate, n=21, 20 | 35.38 ± 11.441 | 34.65 ± 10.840 |
| Day 14 Average flow rate, n=21, 22 | 36.25 ± 11.243 | 36.17 ± 12.772 |
| Day 1 PIFR, n=21, 20 | 51.83 ± 17.286 | 52.90 ± 16.028 |
| Day 14 PIFR, n=21, 22 | 55.70 ± 16.589 | 54.76 ± 17.986 |
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhalation time is defined as the duration of the inhalation(s) when inhaling across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalation time was determined.
| Seconds | Placebo | FF 100 µg |
|---|---|---|
| Day 1, n=21, 20 | 1.71 ± 0.534 | 1.93 ± 0.861 |
| Day 14, n= 21, 22 | 1.60 ± 0.802 | 1.61 ± 0.858 |
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhaled volume is defined as the volume of air (Liters) inhaled during the inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalaled volume was determined.
| Liters | Placebo | FF 100 µg |
|---|---|---|
| Day 1, n=21, 20 | 0.99 ± 0.461 | 1.07 ± 0.480 |
| Day 14, n= 21, 22 | 1.00 ± 0.580 | 0.95 ± 0.541 |
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Peak pressure drop is defined as the maximum pressure drop (kilopascal \[kPa\]) achieved during inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was calculated for each day (Days 1 and 14 of the respective treatment period), and used for subsequent modeling and prediction of dose emission attributes.
| Kilopascal (kpa) | Placebo | FF 100 µg |
|---|---|---|
| Day 1, n=21, 20 | 2.44 ± 1.630 | 2.53 ± 1.560 |
| Day 14, n= 21, 22 | 2.78 ± 1.543 | 2.74 ± 1.609 |
The total emitted dose (TED) is defined as the mass (micrograms) of the nominal dose that passes beyond the throat. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted total emitted dose.
| micrograms | Placebo | FF 100 µg |
|---|---|---|
| Day 1, Nominal TED, n=0, 20 | — | 85.35 ± 1.576 |
| Day 14, Nominal TED, n=0, 22 | — | 85.57 ± 1.857 |
| Day 1, Minimum TED, n=0, 20 | — | 84.84 ± 1.617 |
| Day 14, Minimum TED, n=0, 22 | — | 85.17 ± 1.905 |
| Day 1, Maximum TED, n=0, 20 | — | 85.86 ± 1.639 |
| Day 14, Maximum TED, n=0, 22 | — | 85.97 ± 1.861 |
The ex-throat dose (ETD) and the "nominal ETD" is the mass (micrograms) of active investigational material that passes beyond the throat, nominal being the mean.The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted ETD and ETD \<2 microns.
| micrograms | Placebo | FF 100 µg |
|---|---|---|
| Day 1, Nominal ETD, n=0, 17 | — | 29.37 ± 2.874 |
| Day 14, Nominal ETD, n=0, 12 | — | 29.83 ± 2.528 |
| Day 1, Minimum ETD, n=0, 17 | — | 28.47 ± 3.241 |
| Day 14, Minimum ETD, n=0, 12 | — | 29.35 ± 2.664 |
| Day 1, Maximum ETD, n=0, 17 | — | 30.26 ± 2.598 |
| Day 14, Maximum ETD, n=0, 12 | — | 30.26 ± 2.472 |
| Day 1, ETD <2 microns, n=0, 17 | — | 5.13 ± 0.498 |
| Day 14, ETD <2 microns, n=0, 12 | — | 5.07 ± 0.455 |
| Day 1, Minimum ETD <2 microns, n=0, 17 | — | 4.96 ± 0.459 |
| Day 14, Minimum ETD <2 microns, n=0, 12 | — | 4.99 ± 0.448 |
| Day 1, Maximum ETD <2 microns, n=0, 17 | — | 5.30 ± 0.559 |
| Day 14, Maximum ETD <2 microns, n=0, 12 | — | 5.17 ± 0.476 |
PR, QRS, QT, QTcB, QTcF, and RR were measured at Baseline and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1 for each period. Change from Baseline was calculated as the value at Day 14 minus the Baseline value. QTcB is the QT duration corrected for heart rate by Bazett's formula. QTcF is the QT duration corrected for heart rate by Fridericia's formula.
| milliseconds (msec) | Placebo | FF 100 µg |
|---|---|---|
| Day 1 PR Interval, 30 minutes, n=25, 26 | 6.4 ± 6.37 | 7.5 ± 7.54 |
| Day 1 PR Interval, 1 hour, n=25, 26 | 7.3 ± 6.68 | 8.4 ± 7.17 |
| Day 1 PR Interval, 2 hours, n=25, 26 | 8.0 ± 8.61 | 9.5 ± 10.48 |
| Day 14 PR Interval, Predose, n=24, 23 | 7.8 ± 6.76 | 9.6 ± 9.82 |
| Day 14 PR Interval, 1 hour, n=23, 23 | 8.7 ± 6.74 | 8.3 ± 6.03 |
| Day 14 PR Interval, 4 hours, n=23, 23 | 6.4 ± 3.70 | 8.9 ± 6.86 |
| Day 14 PR Interval, 7 hour, n=23, 23 | 8.3 ± 6.56 | 10.2 ± 10.09 |
| Day 14 PR Interval, 12 hours, n=22, 23 | 7.2 ± 7.50 | 9.7 ± 6.54 |
| Day 1 QRS Interval, 30 minutes, n=25, 26 | 4.6 ± 3.46 | 5.2 ± 4.70 |
| Day 1 QRS Interval, 1 hour, n=25, 26 | 4.1 ± 2.84 | 4.4 ± 3.86 |
| Day 1 QRS Interval, 2 hours, n=25, 26 | 4.0 ± 2.64 | 4.5 ± 3.61 |
| Day 14 QRS Interval, Predose, n=24, 23 | 4.2 ± 3.71 | 4.7 ± 4.29 |
| Day 14 QRS Interval, 1 hour, n=23, 23 | 5.7 ± 3.54 | 5.3 ± 4.71 |
| Day 14 QRS Interval, 4 hours, n=23, 23 | 5.6 ± 3.85 | 4.9 ± 3.93 |
| Day 14 QRS Interval, 7 hours, n=23, 23 | 6.1 ± 5.25 | 4.3 ± 4.22 |
| Day 14 QRS Interval, 12 hours, n=23, 23 | 5.0 ± 4.70 | 4.8 ± 4.02 |
| Day 1 QT Interval, 30 minutes, n=25, 26 | 9.8 ± 8.14 | 10.5 ± 9.57 |
| Day 1 QT Interval, 1 hour, n=25, 26 | 13.1 ± 11.04 | 12.7 ± 11.53 |
| Day 1 QT Interval, 2 hours, n=25, 26 | 17.5 ± 13.88 | 15.5 ± 13.83 |
| Day 14 QT Interval, Predose, n=24, 23 | 12.5 ± 9.81 | 15.5 ± 13.34 |
| Day 14 QT Interval, 1 hour, n=23, 23 | 11.4 ± 6.45 | 15.9 ± 11.11 |
| Day 14 QT Interval, 4 hours, n=23, 23 | 13.3 ± 9.65 | 16.7 ± 12.52 |
| Day 14 QT Interval, 7 hours, n=23, 23 | 14.7 ± 10.94 | 15.3 ± 11.93 |
| Day 14 QT Interval, 12 hours, n=23, 23 | 14.7 ± 10.42 | 24.8 ± 14.93 |
| Day 1 QTcB Interval, 30 minutes, n=25, 26 | 15.4 ± 14.44 | 14.2 ± 11.64 |
| Day 1 QTcB Interval, 1 hour, n=25, 26 | 17.3 ± 13.46 | 17.7 ± 13.18 |
| Day 1 QTcB Interval, 2 hours, n=25, 26 | 13.6 ± 11.07 | 18.2 ± 17.54 |
| Day 14 QTcB Interval, Predose, n=24, 23 | 20.7 ± 15.54 | 17.9 ± 14.92 |
| Day 14 QTcB Interval, 1 hour, n=23, 23 | 16.6 ± 9.43 | 16.2 ± 9.71 |
| Day 14 QTcB Interval, 4 hours, n=23, 23 | 14.7 ± 9.13 | 16.8 ± 9.23 |
| Day 14 QTcB Interval, 7 hours, n=23, 23 | 14.5 ± 10.14 | 19.6 ± 12.03 |
| Day 14 QTcB Interval, 12 hours, n=23, 23 | 13.8 ± 10.70 | 18.5 ± 15.70 |
| Day 1 QTcF Interval, 30 minutes, n=25, 26 | 10.8 ± 9.31 | 11.8 ± 9.30 |
| Day 1 QTcF Interval, 1 hour, n=25, 26 | 11.6 ± 9.57 | 12.6 ± 10.00 |
| Day 1 QTcF Interval, 2 hours, n=25, 26 | 10.4 ± 8.36 | 15.4 ± 12.88 |
| Day 14 QTcF Interval, Predose, n=24, 23 | 14.2 ± 9.92 | 12.6 ± 10.99 |
| Day 14 QTcF Interval, 1 hour, n=23, 23 | 9.3 ± 6.09 | 11.4 ± 9.56 |
| Day 14 QTcF Interval, 4 hours, n=23, 23 | 7.8 ± 6.97 | 15.7 ± 7.41 |
| Day 14 QTcF Interval, 7 hours, n=23, 23 | 9.3 ± 7.77 | 15.0 ± 9.51 |
| Day 14 QTcF Interval, 12 hours, n=23, 23 | 8.8 ± 5.84 | 15.8 ± 11.61 |
| Day 1 RR Interval, 30 minutes, n=25, 26 | 70.4 ± 66.47 | 54.2 ± 44.61 |
| Day 1 RR Interval, 1 hour, n=25, 26 | 93.5 ± 64.97 | 90.7 ± 52.94 |
| Day 1 RR Interval, 2 hours, n=25, 26 | 102.0 ± 61.66 | 80.4 ± 71.51 |
| Day 14 RR Interval, Predose, n=24, 23 | 106.0 ± 73.20 | 103.5 ± 78.48 |
| Day 14 RR Interval, 1 hour, n=23, 23 | 92.5 ± 64.45 | 87.7 ± 63.30 |
| Day 14 RR Interval, 4 hours, n=23, 23 | 92.1 ± 65.93 | 63.6 ± 47.14 |
| Day 14 RR Interval, 7 hours, n=23, 23 | 89.6 ± 63.06 | 74.5 ± 78.18 |
| Day 14 RR Interval, 12 hours, n=23, 23 | 94.4 ± 73.45 | 110.3 ± 101.24 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/25 (0%) | 4/25 (16%) |
| FF 100 µg | — | 0/26 (0%) | 8/26 (30.8%) |
| Event | Placebo | FF 100 µg |
|---|---|---|
| HeadacheNervous system disorders | 0/25 | 3/26 |
| Upper respiratory tract infectionInfections and infestations | 1/25 | 1/26 |
| Abdominal discomfortGastrointestinal disorders | 1/25 | 0/26 |
| ToothacheGastrointestinal disorders | 1/25 | 1/26 |
| Product taste abnormalGeneral disorders | 1/25 | 1/26 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/25 | 0/26 |
| Acute tonsillitisInfections and infestations | 0/25 | 1/26 |
| InfluenzaInfections and infestations | 0/25 | 1/26 |
| Otitis externaInfections and infestations | 0/25 | 1/26 |
| Otitis mediaInfections and infestations | 0/25 | 1/26 |
| Age, Continuous(Years) | FF 100 µg/Placebo or Placebo/FF 100 µg |
|---|---|
| Mean | 8.2 ± 2.08 |
| Sex: Female, Male(Participants) | FF 100 µg/Placebo or Placebo/FF 100 µg |
|---|---|
| Female | 13 |
| Male | 14 |
| Race/Ethnicity, Customized(participants) | FF 100 µg/Placebo or Placebo/FF 100 µg |
|---|---|
| African American/African Heritage | 9 |
| White | 16 |
| African American/African Heritage & White | 1 |
| Unknown; Child Was Adopted | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of May 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 2 years 8 months after primary completion. A results delay was requested in Mar 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone furoate